Article in The Journal of allergy and clinical immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Kohei HasegawaDepartment of Emergency Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.
Carlos A CamargoDepartment of Emergency Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.
Jonathan M MansbachHarvard Medical School, Boston, Mass; Department of Pediatrics, Boston Children's Hospital, Boston, Mass. Electronic address: jonathan.mansbach@childrens.harvard.edu.
Funding
Host genetics, early-life microbiome, and childhood asthma: MARC-43 BostonUH3OD023253 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARLOS ARTURO CAMARGO · 2018 to 2026
$12.1M
Nasal microRNA during bronchiolitis and age 6y asthma phenotypes: MARC-35 cohortR01AI127507 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CAMARGO, CARLOS ARTURO, FREISHTAT, ROBERT J · 2017 to 2021
$8.0M
Host genetics, early-life microbiome, and childhood asthma: MARC-43 BostonUG3OD023253 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CAMARGO, CARLOS ARTURO · 2016 to 2024
$6.8M
Airway dual-transcriptomics in bronchiolitis and risk of asthma: MARC-35 cohortR01AI137091 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HASEGAWA, KOHEI · 2018 to 2022
$4.3M
Airway metagenome & metabolome in bronchiolitis and risk of asthma: MARC-35 cohortR01AI134940 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HASEGAWA, KOHEI · 2018 to 2022
$4.0M
Infant blood epigenome and risks of IgE sensitization, obesity, and asthma: MARC-35/43 cohortsR01AI148338 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI CAMARGO, CARLOS ARTURO, LIANG, LIMING · 2020 to 2023
$2.5M
Microbiome-host interplay in viral respiratory infections: A tracheostomy cohortR56AI163013 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI MANSBACH, JONATHAN M · 2021 to 2021
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Role of nasal microbiota and host response in infants with respiratory syncytial virus infection: Causal questions about respiratory outcomes. · full record | OpenQuestion